RNAZ
TransCode Therapeutics, Inc.NASDAQHealthcare$8.60+4.19%ClosedMarket Cap: $7.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.24
P/S
0.00
EV/EBITDA
-0.20
DCF Value
$9.74
FCF Yield
-176.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-684.9%
ROA
-519.1%
ROIC
-754.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $0.00 | -Infinity% | $-4.6M | $-4.9M | $-5.82 | — |
| Q2 2025 | $0.00 | -Infinity% | $-4.2M | $-4.3M | $-5.13 | — |
| Q1 2025 | $0.00 | -Infinity% | $-3.2M | $-12.1M | $-70.28 | — |
| Q4 2024 | $0.00 | NaN% | $-5.1M | $-5.9M | $-16.61 | — |
| FY 2024 | $0.00 | -Infinity% | $-15.7M | $-16.8M | $-47.14 | — |
| Q3 2024 | $0.00 | -Infinity% | $-2.2M | $-2.3M | $15.34 | — |
| Q2 2024 | $0.00 | NaN% | $-5.1M | $-5.2M | $-24.42 | — |
| Q1 2024 | $0.00 | NaN% | $-3.3M | $-3.3M | $-21.45 | — |
| Q4 2023 | $0.00 | -Infinity% | $-4.1M | $-4.1M | $-761.16 | — |
| FY 2023 | $0.00 | -Infinity% | $-19.4M | $-18.5M | $-3,453.53 | — |
| Q3 2023 | $0.00 | -Infinity% | $-5.3M | $-5.3M | $-48.44 | — |
| Q2 2023 | $0.00 | -Infinity% | $-5.1M | $-4.3M | $-142.38 | — |